Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sprifermin in Acute Cartilage Injury of the Knee
NCT01066871Phase 2Terminated
- Sponsor
- Merck KGaA
- Start
- Mar 2010
- Primary completion
- Apr 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sprifermin in Cartilage Injury of the Knee (4 arms), sponsored by Merck KGaA. Primary endpoint: Percent Change From Baseline in Cartilage Defect Volume at 12 months. Started Mar 2010; status: terminated.
02
Drugs
sprifermin
03
Conditions
Cartilage Injury of the Knee
Beyond the preview
Go deeper on NCT01066871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01066871.